| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT07284420 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to… |
Trial sites expanded: 10 -> 13 locations |
| 2026-06-02 | NCT07294170 ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy… |
Trial sites expanded: 10 -> 15 locations |
| 2026-05-29 | NCT07091630 A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP |
Trial sites expanded: 43 -> 56 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07638566 A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent… | Phase 2/3 | Not Yet Recruiting |
| 2026-05-28 | NCT07610564 A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults… | Phase 1 | Not Yet Recruiting |
| 2026-05-28 | NCT07612020 A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an… | Phase 1 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting |
| Phase 2/3 | |||
| NCT07638566 | A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent… | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Not Yet Recruiting |
| Phase 2 | |||
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to… | AChR-Ab Seropositive Generalized Myasthenia Gravis | Recruiting |
| Phase 1 | |||
| NCT07612020 | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an… | Healthy Volunteers | Recruiting |
| NCT07610564 | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults… | Multifocal Motor Neuropathy (MMN) | Not Yet Recruiting |
| Not specified | |||
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy… | Myasthenia Gravis | Recruiting |